Developer docs
API playgroundTry for free, no card

Search company profiles

4DMT

Full company profile

uuid00sjok4

Namestring
4DMT
Legal namestring
4D Molecular Therapeutics
Websiteurl
4dmt.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

4D Molecular Therapeutics (4DMT) is a clinical-stage biotechnology company developing genetic medicines through a proprietary directed evolution platform that creates customized adeno-associated virus (AAV) vectors tailored to specific disease applications. The company's core technology differs from competitors in that vectors are invented via iterative directed evolution rather than relying on naturally occurring or minimally modified capsids. Clinical development is concentrated in two therapeutic areas: retinal diseases and pulmonary diseases. The lead clinical candidate, 4D-150, is an intravitreally-administered gene therapy for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) that has demonstrated up to 90% reduction in anti-VEGF injection burden and maintenance of visual acuity at two years in clinical trials. The second clinical candidate, 4D-710, is an inhalable gene therapy designed to deliver functional CFTR genes to lung cells in cystic fibrosis patients who do not adequately respond to existing CFTR modulators (approximately 10% of CF patients).

The company's pipeline is supported by multiple regulatory milestones: 4D-150 in wet AMD has completed Phase 3 enrollment (February 2026), 4D-150 in DME is advancing to Phase 3 following FDA RMAT designation (May 2025), and 4D-710 continues in CF development with CF Foundation support. 4DMT has also expanded beyond its core indications through a partnership with Arbor Biotechnologies to address central nervous system diseases using its directed evolution platform.

4DMT is pre-revenue with no commercialized products and headquarters in Emeryville, California. The revenue model contemplates future product sales upon regulatory approval, supplemented by licensing and partnership economics including upfront payments, development milestones, and royalties. Material partnership deals include the Astellas license (potential value up to $962 million, July 2023), the Otsuka collaboration focused on retinal Phase 3 development (potential value up to $420 million, October 2025), the Arbor Biotechnologies CNS collaboration (January 2023), and ongoing Cystic Fibrosis Foundation investment. The company acquired an eye disease asset from a Fortress Biotech subsidiary in September 2023 to broaden its retinal pipeline. Distribution upon commercialization is expected to flow through specialist healthcare providers (retina specialists, pulmonologists) and/or partnership with larger pharmaceutical companies for specific markets.

Short descriptiontext

4D Molecular Therapeutics is a clinical-stage biotech using proprietary directed evolution to invent customized AAV gene therapies, with lead candidate 4D-150 in wet AMD and DME Phase 3 trials and 4D-710 for cystic fibrosis pulmonary delivery.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersEmeryville, United States
HQ citystring
Emeryville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene therapy development, AAV vector platform, directed evolution biotechnology, retinal disease therapeutics, cystic fibrosis treatment
Industry1 code
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Genetic Medicines
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Product Development & Clinical Trials
TypeOne Time License
Description

Pre-revenue clinical-stage company developing genetic medicines. No commercialized products yet. Revenue will come from product sales upon regulatory approval.

4dmoleculartherapeutics.com
2Licensing & Partnership Deals
TypeLicensing Royalties
Description

Biopharmaceutical companies license 4DMT's proprietary vectors and technologies for specific applications. Examples include Astellas deal (up to $962M potential) and Otsuka deal (up to $420M potential), generating upfront payments, development milestones, and royalties.

4dmoleculartherapeutics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

4DMT is a clinical-stage biotechnology company that develops customized genetic medicines using a proprietary directed evolution platform for engineering adeno-associated virus (AAV) vectors. The company is advancing clinical-stage gene therapy candidates including 4D-150 (intravitreally administered for wet AMD and diabetic macular edema) and 4D-710 (inhalable for cystic fibrosis), generating revenue through biopharmaceutical licensing deals and development partnerships.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 90% reduction in wet AMD treatment burden with intravitreally administered 4D-150
+2 more records
Product overview1 text field

4DMT is a clinical-stage genetic medicine company developing a portfolio of proprietary gene therapy product candidates using its evolved AAV vector platform. The company's lead products include 4D-150 (intravitreally-administered gene therapy for wet AMD and DME showing 90% reduction in anti-VEGF injection burden) and 4D-710 (inhalable gene therapy for cystic fibrosis). The 4D Vector Platform leverages directed evolution to create customized vectors optimized for specific diseases, primarily focused in retina and pulmonology therapeutic areas.

Product and service3 records
14D-150
CategoryClinical Product Candidate - Gene Therapy
Description

A proprietary intravitreally-administered gene therapy product candidate for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Uses customized AAV vectors to deliver anti-VEGF expression, demonstrating 90% reduction in treatment burden versus standard-of-care anti-VEGF injections in clinical trials. Targets patients with retinal vascular diseases who currently require frequent eye injections.

24D-710
CategoryClinical Product Candidate - Gene Therapy
Description

An inhalable gene therapy candidate for cystic fibrosis, designed to deliver functional CFTR genes to lung cells using aerosolized AAV vectors. Targets CF patients who do not respond to existing CFTR modulators (approximately 10% of CF patient population). Delivered via aerosol inhalation to restore CFTR production in the lungs.

34D Vector Platform
CategoryTechnology Platform - Licensed to Partners
Description

A proprietary genetic medicine engine using directed evolution to invent and develop customized AAV (adeno-associated virus) vectors optimized for specific disease applications. The platform is licensed to biopharmaceutical partners (including Astellas and Otsuka) for development of gene therapies in specific therapeutic areas, generating upfront payments, development milestones, and royalties.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

Otsuka partnership with 4DMT focused on retinal gene therapy Phase 3 plans. Potential deal value of up to $420 million, with cash aimed at supporting 4DMT's retinal gene therapy Phase 3 development programs.

Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-07-01
Description

Astellas licensed 4DMT's AAV viral vector for rare eye disease gene therapy development. Potential total deal value up to $962 million including upfront, development, and commercial milestones, plus royalties.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Partnership to develop genetic medicines for CNS diseases. Combines 4DMT's directed evolution vector platform with Arbor's genomic medicine capabilities for central nervous system applications.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

4DMT

Genetic Medicines4dmt.com

4D Molecular Therapeutics is a clinical-stage biotech using proprietary directed evolution to invent customized AAV gene therapies, with lead candidate 4D-150 in wet AMD and DME Phase 3 trials and 4D-710 for cystic fibrosis pulmonary delivery.

What 4DMT does

4D Molecular Therapeutics (4DMT) is a clinical-stage biotechnology company developing genetic medicines through a proprietary directed evolution platform that creates customized adeno-associated virus (AAV) vectors tailored to specific disease applications. The company's core technology differs from competitors in that vectors are invented via iterative directed evolution rather than relying on naturally occurring or minimally modified capsids. Clinical development is concentrated in two therapeutic areas: retinal diseases and pulmonary diseases. The lead clinical candidate, 4D-150, is an intravitreally-administered gene therapy for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) that has demonstrated up to 90% reduction in anti-VEGF injection burden and maintenance of visual acuity at two years in clinical trials. The second clinical candidate, 4D-710, is an inhalable gene therapy designed to deliver functional CFTR genes to lung cells in cystic fibrosis patients who do not adequately respond to existing CFTR modulators (approximately 10% of CF patients).

The company's pipeline is supported by multiple regulatory milestones: 4D-150 in wet AMD has completed Phase 3 enrollment (February 2026), 4D-150 in DME is advancing to Phase 3 following FDA RMAT designation (May 2025), and 4D-710 continues in CF development with CF Foundation support. 4DMT has also expanded beyond its core indications through a partnership with Arbor Biotechnologies to address central nervous system diseases using its directed evolution platform.

4DMT is pre-revenue with no commercialized products and headquarters in Emeryville, California. The revenue model contemplates future product sales upon regulatory approval, supplemented by licensing and partnership economics including upfront payments, development milestones, and royalties. Material partnership deals include the Astellas license (potential value up to $962 million, July 2023), the Otsuka collaboration focused on retinal Phase 3 development (potential value up to $420 million, October 2025), the Arbor Biotechnologies CNS collaboration (January 2023), and ongoing Cystic Fibrosis Foundation investment. The company acquired an eye disease asset from a Fortress Biotech subsidiary in September 2023 to broaden its retinal pipeline. Distribution upon commercialization is expected to flow through specialist healthcare providers (retina specialists, pulmonologists) and/or partnership with larger pharmaceutical companies for specific markets.

4DMT firmographics

Firmographics
Name
4DMT
Legal name
4D Molecular Therapeutics
Website
https://4dmt.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
51–100 employees
Short description
4D Molecular Therapeutics is a clinical-stage biotech using proprietary directed evolution to invent customized AAV gene therapies, with lead candidate 4D-150 in wet AMD and DME Phase 3 trials and 4D-710 for cystic fibrosis pulmonary delivery.
Ownership category
akta.pro rank

4DMT industry classification

Industry
Product category
Genetic Medicines
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Gene therapy development
  • AAV vector platform
  • Directed evolution biotechnology
  • Retinal disease therapeutics
  • Cystic fibrosis treatment

Where 4DMT is headquartered

Location

Headquarters

HQ city
Emeryville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

4DMT business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Product Development & Clinical Trials: Pre-revenue clinical-stage company developing genetic medicines. No commercialized products yet. Revenue will come from product sales upon regulatory approval.
  2. Licensing & Partnership Deals: Biopharmaceutical companies license 4DMT's proprietary vectors and technologies for specific applications. Examples include Astellas deal (up to $962M potential) and Otsuka deal (up to $420M potential), generating upfront payments, development milestones, and royalties.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

4DMT product offering

Product offering

Core offering

4DMT is a clinical-stage biotechnology company that develops customized genetic medicines using a proprietary directed evolution platform for engineering adeno-associated virus (AAV) vectors. The company is advancing clinical-stage gene therapy candidates including 4D-150 (intravitreally administered for wet AMD and diabetic macular edema) and 4D-710 (inhalable for cystic fibrosis), generating revenue through biopharmaceutical licensing deals and development partnerships.

Product overview

4DMT is a clinical-stage genetic medicine company developing a portfolio of proprietary gene therapy product candidates using its evolved AAV vector platform. The company's lead products include 4D-150 (intravitreally-administered gene therapy for wet AMD and DME showing 90% reduction in anti-VEGF injection burden) and 4D-710 (inhalable gene therapy for cystic fibrosis). The 4D Vector Platform leverages directed evolution to create customized vectors optimized for specific diseases, primarily focused in retina and pulmonology therapeutic areas.

Differentiator

Problem solved

Functional benefit

Products and services

  • 4D-150 A proprietary intravitreally-administered gene therapy product candidate for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Uses customized AAV vectors to deliver anti-VEGF expression, demonstrating 90% reduction in treatment burden versus standard-of-care anti-VEGF injections in clinical trials. Targets patients with retinal vascular diseases who currently require frequent eye injections.
  • 4D-710 An inhalable gene therapy candidate for cystic fibrosis, designed to deliver functional CFTR genes to lung cells using aerosolized AAV vectors. Targets CF patients who do not respond to existing CFTR modulators (approximately 10% of CF patient population). Delivered via aerosol inhalation to restore CFTR production in the lungs.
  • 4D Vector Platform A proprietary genetic medicine engine using directed evolution to invent and develop customized AAV (adeno-associated virus) vectors optimized for specific disease applications. The platform is licensed to biopharmaceutical partners (including Astellas and Otsuka) for development of gene therapies in specific therapeutic areas, generating upfront payments, development milestones, and royalties.

Quantifiable outcome

  • 90% reduction in wet AMD treatment burden with intravitreally administered 4D-150
  • +2 more outcomes

Companies that use 4DMT

Customer profile

Segments2 records

Ideal customer profiles3 records

4DMT technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

4DMT partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered major and core.

  • OtsukamajorStrategic or Co-development Partner · 1 October 2025Otsuka partnership with 4DMT focused on retinal gene therapy Phase 3 plans. Potential deal value of up to $420 million, with cash aimed at supporting 4DMT's retinal gene therapy Phase 3 development programs.
  • Astellas PharmamajorOEM/ Whitelabel/ Licensing Partner · 1 July 2023Astellas licensed 4DMT's AAV viral vector for rare eye disease gene therapy development. Potential total deal value up to $962 million including upfront, development, and commercial milestones, plus royalties.
  • Arbor BiotechnologiescoreStrategic or Co-development Partner · 1 January 2023Partnership to develop genetic medicines for CNS diseases. Combines 4DMT's directed evolution vector platform with Arbor's genomic medicine capabilities for central nervous system applications.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

4DMT competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

4DMT financial estimates

Financial estimate

Revenue estimate

Valuation estimate

4DMT leadership team

Management profile

Number of profiles

4DMT funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

4DMT M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 4DMT

What does 4DMT do?

4DMT is a clinical-stage biotechnology company that develops customized genetic medicines using a proprietary directed evolution platform for engineering adeno-associated virus (AAV) vectors. The company is advancing clinical-stage gene therapy candidates including 4D-150 (intravitreally administered for wet AMD and diabetic macular edema) and 4D-710 (inhalable for cystic fibrosis), generating revenue through biopharmaceutical licensing deals and development partnerships.

Is 4DMT a public or private company?

4DMT is a private company. It is classified as unknown and is currently operating.

When was 4DMT founded?

4DMT was founded in 2013. It employs 51 to 100 people.

Where is 4DMT based?

4DMT is headquartered in Emeryville, United States, in the North America region.

How does 4DMT make money?

Two revenue lines are on record. Product Development & Clinical Trials are the primary driver. The others are licensing & Partnership Deals.

Does 4DMT have an API?

No public API is recorded for 4DMT.

What industry is 4DMT in?

4DMT's product category is Genetic Medicines. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & Financial4DMT To Participate In Upcoming Investor Conferences4DMT will participate in multiple investor conferences in November and December 2026, including Guggenheim, Stifel, Jefferies, Evercore, Citi, Piper Sandler, and Barclays. The company's lead product candidate 4D-150 is in Phase 3 for wet AMD and diabetic macular edema, while 4D-710 is a genetic medicine for cystic fibrosis.Longevity.Technology4DMT advances 4D-150 into Phase 3 for diabetic macular edema4DMT enrolled first patients in its Phase 3 4SIGHT trial for 4D-150 in treatment-naïve diabetic macular edema, with 514 patients and aflibercept comparator. Updated two-year SPECTRA Part 1 data showed a mean BCVA gain of 10.8 letters and no ocular serious adverse events. The company claims alignment with FDA and EMA on potential regulatory filings.HCP Live4D-150 Reduces Injection Burden in DME, Paving Way for FDA-Backed Phase 34DMT announced positive interim data from the SPECTRA clinical trial for its drug candidate 4D-150 in treating diabetic macular edema (DME), demonstrating sustained visual gains and a significant reduction in injection burden compared to standard of care. Following this review, the US Food and Drug Administration (FDA) aligned with 4DMT on a single Phase 3 trial design, allowing the company to proceed directly to registrational studies without conducting further Part 2 trials. This regulatory alignment supports 4DMT's strategic focus on advancing 4D-150 for wet AMD and DME indications.BioWorldFinancings for June 30, 2026On June 30, 2026, biopharma and med-tech companies including 4DMT, Akari, Biobot, and Neurolife raised money through public or private financings. The list of companies is provided in the BioWorld brief.GlobeNewswire4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD4DMT completed global enrollment for 4FRONT-2, a Phase 3 trial of 4D-150 in wet AMD, about four months ahead of projections. The trial over-enrolled, with final randomization expected in Q3 2026 and 52-week topline data in H2 2027.Longevity.Technology4DMT reports positive interim Phase 1 AEROW data for 4D-710 in cystic fibrosis lung disease4D Molecular Therapeutics announced positive interim clinical results from its Phase 1 AEROW trial evaluating 4D-710, an investigational gene therapy for cystic fibrosis lung disease in patients ineligible for or intolerant of CFTR modulator therapies. Across 16 participants across four dose cohorts, the therapy demonstrated good tolerability with no new safety events in higher-dose cohorts through up to 3.5 years of follow-up. The 2.5E14 vector genomes dose was selected for Phase 2 development based on evidence of clinically meaningful activity, including improvements in lung function and patient-reported respiratory quality of life, with enrollment of six additional participants expected in H1 2026.GlobeNewswire4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases4DMT and Arbor Biotechnologies announced a partnership to co-develop and co-commercialize up to six AAV-delivered CRISPR/Cas-based therapeutics for CNS diseases, with a 50:50 profit share. The first product candidate will target amyotrophic lateral sclerosis (ALS), with additional targets expected in rare and large patient populations.GlobeNewswire4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases4DMT and Arbor Biotechnologies announced a partnership to co-develop and co-commercialize up to six AAV-delivered CRISPR/Cas-based therapeutics for CNS diseases, with a 50:50 profit share. The first product candidate will target amyotrophic lateral sclerosis (ALS), with additional targets expected in rare and large patient populations.GlobeNewswire4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases4DMT and Arbor Biotechnologies announced a partnership to co-develop and co-commercialize up to six AAV-delivered CRISPR/Cas-based therapeutics for CNS diseases, with a 50:50 profit share. The first product candidate will target amyotrophic lateral sclerosis (ALS), with additional targets expected in rare and large patient populations.GlobeNewswire4DMT Appoints Uneek Mehra as Chief Financial and Business Officer4DMT appointed Uneek Mehra as Chief Financial and Business Officer, succeeding August Moretti, who is retiring. Mehra brings over 27 years of experience, including CFO roles at Myovant Sciences and Novartis. He will lead finance, business development, and precommercial functions, reporting to CEO David Kirn.